Dr. Carol Satler discusses the recent (Nov 2018) FDA approval of Gamifant® (emapalumab-lzsg), the first and only treatment indicated for primary hemophagocytic lymphohistiocytosis (HLH).
Listen to more health-related stories and research updates at www.hpr.fm
Негізгі бет FDA Approval of Gamifant® (emapalumab-Iszg) for Primary HLH Treatment
No video
Пікірлер: 1